The emergence of increasingly sophisticated models for the online distribution of pharmaceuticals raises particularly complex legal questions concerning the classification of platform activities, the liability of healthcare professionals, and the effectiveness of public oversight—especially in contexts where technology is deployed to circumvent formally established regulatory prohibitions.

Within this framework lies the case recently disclosed by the Supreme People’s Procuratorate of China (最高人民检察院), involving the disguised online sale of prohibited medicines through ostensibly “medical consultations” conducted on e-commerce platforms.

According to the findings of the investigative authorities, certain clinics operating through digital “medicine search” services enabled users to purchase medicines included in the list of substances prohibited from online sale, without any genuine medical examination taking place. The system relied on automated question-and-answer chat procedures devoid of any meaningful clinical assessment, which were subsequently followed by the direct shipment of the medicines via courier.

The central issue in the case concerned not merely the breach of regulations governing the e-commerce of pharmaceuticals, but more fundamentally the legal qualification of the relationship established with the user. Although the operators involved sought to frame their activities within the scope of healthcare services and telemedicine, the prosecuting authority determined that the use of automated questionnaires constituted nothing more than a formal simulation of medical practice, lacking the substantive elements of diagnosis and therapeutic care.

Through public hearings and the coordinated involvement of experts in the pharmaceutical sector, health authorities, market supervision agencies, and representatives of digital platforms, a principle of broader significance was affirmed: where the healthcare interaction is merely apparent and serves exclusively as a conduit for the delivery of medicines, the prevailing legal characterization remains that of a commercial transaction in pharmaceutical products.

The regulatory implications are considerable. The case has effectively led to an expansion of the supervisory powers of market regulation authorities, extending oversight to conduct formally presented as healthcare services, while also promoting the development of a coordinated governance framework between health authorities and e-commerce regulatory bodies.

Equally noteworthy is the investigative methodology adopted by the Procuratorate, grounded in advanced legal monitoring techniques employing big data analytics, simulated online purchases, electronic evidence collection, and on-site inspections. This approach underscores how, in digital markets, the protection of the public interest increasingly depends on supervisory tools capable of capturing the economic substance of transactions beyond their contractual form.

The case further illustrates that digital platforms can no longer be regarded as neutral technological intermediaries. The subsequent regulatory responses—including strengthened vendor verification mechanisms, transaction risk alert systems, sample-based pharmaceutical inspections, and inter-agency cooperation protocols—reflect a gradual shift toward enhanced accountability for digital ecosystems in the management of health-related risks.

Overall, the case highlights the growing attention of Chinese authorities to the risks associated with online pharmaceutical distribution, as well as their increasing reliance on technologically enabled legal oversight to counteract evolving forms of regulatory evasion.

By Andrea Sorgato – andrea.sorgato@studiozunarelli.com